By Fineline Cube 
Shanghai ChemPartner Co., Ltd. (SHE: 300149) and Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a strategic cooperation framework agreement to integrate ChemPartner’s full‑spectrum CRO/CDMO capabilities with Fosun’s innovation pipeline, streamlining key drug development processes.
Deal Overview
| Element | Details |
|---|---|
| Companies | ChemPartner + Fosun Pharma |
| Agreement Type | Strategic cooperation framework |
| Date Signed | 25 Nov 2025 |
| Focus | End‑to‑end drug development efficiency |
| Geography | China‑centric with global ambitions |
ChemPartner’s Service Platform
Leading domestic CRO & CDMO covering:
- Biologics: Early‑stage antibody discovery, pharmacology/efficacy, PK, early toxicology
- Small Molecules: Chemistry R&D, process development, manufacturing
- New Modalities: XDC, Peptides, Oligonucleotides, PROTACs
- One‑Stop Model: Integrated services from target to clinical supply
Fosun Pharma’s Innovation Engine
Therapeutic Areas: Oncology, immuno‑inflammation, chronic diseases (cardiovascular, renal, metabolic), CNS disorders
Technology Platforms: Antibody/ADC, Cell Therapy, Small Molecules
Strategic Positioning: Radiopharmaceuticals, RNA, Gene Therapy, AI drug discovery
Pipeline Depth: Significant project reserves across Class 1 innovations
Strategic Rationale & Market Context
- Synergy: ChemPartner’s service breadth matches Fosun’s diversified R&D needs
- Speed & Quality: One‑stop model reduces handoff friction, accelerates timelines
- Market Growth: China’s biotech CRO sector expanding at >20 % CAGR
- Competitive Moat: Vertically integrated partnership creates end‑to‑end innovation engine
Forward‑Looking Statements
This brief contains forward‑looking statements regarding partnership execution and development milestones. Actual outcomes may differ due to regulatory, competitive, and operational risks.-Fineline Info & Tech